Enable JavaScript to visit this website.

ASPIRE Dermatology Landing Page

Pfizer is proud to offer the 2018 ASPIRE Dermatology Research Awards

This ASPIRE program is part of Pfizer's commitment to supporting research in inflammatory and immune-mediated skin diseases.

Mission

To support basic science, translational, clinical and health services research through a competitive grant program that increases medical knowledge in inflammatory and immune-mediated skin diseases.

Background

Scientific research continues to advance our knowledge and understanding of inflammatory and immune-mediated skin diseases. The 2018 ASPIRE Dermatology Research Awards will fund meritorious research proposals that have the potential to improve patient care.

Areas of Focus

Pfizer is interested in supporting studies in the following areas. Applications comprising laboratory investigation, clinical, or health services research will be considered.

General

  • Clinical research related to inflammatory or immune-mediated skin diseases
  • Basic research in the etiology of inflammatory or immune-mediated skin diseases including clarification of the intracellular immune cascade in the skin

Atopic Dermatitis

  • Approaches to improving adherence to topical therapy for atopic dermatitis
  • Approaches to improving management of atopic dermatitis (e.g. early therapy, prevention of flares, long-term maintenance, sequential treatment, bimodal therapy, etc.)
  • Exploring patient/caregiver/parent satisfaction with therapy and factors affecting switching therapies or non-compliance
  • Exploring patient/caregiver/parent treatment preferences (e.g. different treatment classes or differences between oral, injectable, and topical therapies)
  • Exploring patient/caregiver/parent burden of mild to moderate atopic dermatitis
  • Exploring AD comorbidities and impact and/or prevalence

PDE4 & crisaborole

  • Exploring the impact of crisaborole on patient-reported outcomes (e.g. pruritus, sleep, QoL)
  • Evaluating compatibility of crisaborole with other topical agents used commonly by atopic dermatitis patients
  • Evaluating use of crisaborole in combination or in sequence with other agents
  • Exploration of the role of PDE4 inhibition in inflammatory or immune mediated skin disease
  • Exploration of the role of PDE4 inhibition in itch
  • Research related to, but not limited to, the use of crisaborole in the treatment of inflammatory or immune-mediated skin disorders with an unmet therapeutic need

Available Awards

The 2018 ASPIRE Dermatology Disease Research Awards are up to a maximum of $150,000 each. Research projects are expected to complete within 2 years of study start. Up to 5 awards may be given.